NTINEUROTECH INTERNATIONAL LIMITED
Announcement history available from 1 August 2025
Fromto
| Date / Time | Title | Type | MS | Report Codes | |
|---|---|---|---|---|---|
| 17 Aug 2026, 19:33 | Appointment of Executive Chairman | Other | — | 12017 | |
| 13 Aug 2026, 23:39 | Becoming a substantial holder | Substantial Holders | — | 02001 | |
| 12 Aug 2026, 04:01 | Secondary Trading Notice | Securities Administration | — | 06018 | |
| 12 Aug 2026, 03:58 | Application for quotation of securities - NTI | Other | — | 06020 | |
| 4 Aug 2026, 19:27 | Proposed issue of securities - NTI | Securities Administration | — | 06013 | |
| 4 Aug 2026, 19:27 | Proposed issue of securities - NTI | Securities Administration | — | 06013 | |
| 4 Aug 2026, 19:26 | Receipt of Binding Commitments for $4.5m Placement | Capital Raising | MS | 06003, 09014 | |
| 31 July 2026, 20:59 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19004, 19009 | |
| 31 July 2026, 19:22 | Trading Halt | Trading Halt / Suspension | MS | 09007 | |
| 30 July 2026, 19:00 | NTI164 Phase II/III Autism Data Accepted for Publication | Company Update | — | 11001 | |
| 22 July 2026, 02:43 | Secondary Trading Notice | Securities Administration | — | 06018 | |
| 22 July 2026, 02:37 | Application for quotation of securities - NTI | Other | — | 06020 | |
| 15 July 2026, 22:11 | Neurotech secures $3.15 million R&D tax incentive loan | Periodic Reports | MS | 03014, 12008 | |
| 14 July 2026, 18:50 | US FDA clears IND for NTI164 | Company Update | MS | 11001 | |
| 14 July 2026, 05:16 | Notification regarding unquoted securities - NTI | Other | — | 06021 | |
| 13 July 2026, 19:32 | Proposed issue of securities - NTI | Securities Administration | — | 06013 | |
| 2 July 2026, 19:35 | NTI secures Notices of Allowance for US patent applications | Company Update | MS | 11001 | |
| 30 June 2026, 02:39 | Notification of cessation of securities - NTI | Other | — | 06027 | |
| 29 Apr 2026, 19:42 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19003, 19008 | |
| 29 Apr 2026, 01:20 | Change of Director's Interest Notice | Director Interests | — | 02009 | |
| 29 Apr 2026, 01:18 | Notification of cessation of securities - NTI | Other | — | 06027 | |
| 24 Apr 2026, 04:40 | Ceasing to be a substantial holder | Substantial Holders | — | 02003 | |
| 13 Apr 2026, 19:19 | Neurotech to present at Ignite Investment Summit Hong Kong | Presentations | — | 03026 | |
| 1 Apr 2026, 05:17 | Change of Director's Interest Notice x 4 | Director Interests | — | 02009 | |
| 31 Mar 2026, 05:44 | Secondary Trading Notice | Securities Administration | — | 06018 | |
| 31 Mar 2026, 05:37 | Application for quotation of securities - NTI | Other | — | 06020 | |
| 23 Mar 2026, 20:28 | Neurotech to present at NWR Virtual Healthcare Conference | Presentations | — | 14014 | |
| 18 Mar 2026, 20:33 | Corporate Presentation | Presentations | — | 03026 | |
| 17 Mar 2026, 20:32 | NTI initiates First Clinical Site for Phase 3 ASD Trial | Company Update | MS | 11001 | |
| 13 Mar 2026, 01:10 | Results of General Meeting | Meetings & Governance | — | 08003 | |
| 27 Feb 2026, 05:15 | Appendix 4D & Half Year Report | Financial Results | MS | 03004, 03009, 03010, 03015, 03019 | |
| 23 Feb 2026, 20:45 | Positive 90-day GLP toxicology study results in non-rodents | Company Update | MS | 11001 | |
| 18 Feb 2026, 20:38 | NTI Collaborates with University of Sydney in Rett program | Company Update | — | 11001 | |
| 11 Feb 2026, 03:10 | Notice of General Meeting/Proxy Form | Meetings & Governance | — | 08004, 08007, 16002 | |
| 2 Feb 2026, 20:36 | Approval received for NTI164 Phase 3 Clinical Study in ASD | Company Update | MS | 11001 | |
| 30 Jan 2026, 19:56 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19002, 19007 | |
| 15 Jan 2026, 20:35 | PANS Data Published in Leading Scientific Journal | Company Update | — | 11001 | |
| 25 Dec 2025, 00:32 | Secondary Trading Notice | Securities Administration | — | 06018 | |
| 25 Dec 2025, 00:31 | Application for quotation of securities - NTI | Other | — | 06020 | |
| 23 Dec 2025, 23:03 | Change of Director's Interest Notice | Director Interests | — | 02009 | |
| 23 Dec 2025, 23:01 | Notification of cessation of securities - NTI | Other | — | 06027 | |
| 17 Dec 2025, 21:02 | Proposed issue of securities - NTI | Securities Administration | — | 06013 | |
| 17 Dec 2025, 21:02 | Proposed issue of securities - NTI | Securities Administration | — | 06013 | |
| 17 Dec 2025, 21:02 | Binding Commitments Received for a $4 Million Placement | Capital Raising | MS | 06003, 09014 | |
| 15 Dec 2025, 20:15 | Trading Halt | Trading Halt / Suspension | MS | 09007 | |
| 20 Nov 2025, 23:25 | Results of Meeting | Meetings & Governance | — | 08003 | |
| 20 Nov 2025, 20:20 | Presentation to 2025 Annual General Meeting | Presentations | — | 03026, 15002 | |
| 12 Nov 2025, 20:53 | Neurotech receives $4.73m R&D Tax Incentive Refund | Periodic Reports | MS | 03014 | |
| 28 Oct 2025, 22:13 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19001, 19006 | |
| 21 Oct 2025, 02:21 | Notice of Annual General Meeting/Proxy Form | Meetings & Governance | — | 08001, 08004, 16002 |
1–50 of 56
1 / 2